Home/Pipeline/PCSK9 Program

PCSK9 Program

Cardiometabolic Disease

Candidate-EnabledActive

Key Facts

Indication

Cardiometabolic Disease

Phase

Candidate-Enabled

Status

Active

Company

nChroma Bio

About nChroma Bio

nChroma Bio is a private, preclinical-stage biotech founded in 2020 and headquartered in Boston, MA, USA. The company is pioneering a disease-first approach to genetic medicine, integrating epigenetic and gene-editing cargoes with a modular delivery platform (LNPs for liver, eVLPs for extrahepatic tissues) to create durable, targeted therapies. Its pipeline includes a Phase 1/2 candidate for chronic HBV and earlier research programs in cardiometabolic and CNS diseases, positioning it to address significant unmet needs in both hepatic and non-liver indications.

View full company profile

Therapeutic Areas

Infectious Disease Cardiometabolic Central Nervous System

Other Cardiometabolic Disease Drugs

Drug	Company	Phase	Status
PCSK9 Multiplex Program	nChroma Bio	Research	Active
Undisclosed Peripheral	Manifold Bio	Pre-clinical	Active
Undisclosed (Cardiometabolic)	SanegeneBio	Phase 1	Active